October 28, 2015 | Israeli bio-medical company SmartZyme has raised $4 million from healthcare investment fund Orbimed. The new injection of capital will enable the company to further develop their platform for protein design, which the team is currently using to build a glucose monitoring system, as well as other diabetes treatments. Founded in 2013 and run by CEO and Co-Founder Shilo Ben-Zeev, SmartZyme holds offices in Minneapolis, Minnesota and Ness Ziona, Israel.
Related posts
Israeli AI Safety Tool Among TIME’S Best Inventions For 2024
October 31, 2024
TAU Team Discovers Mechanism To Eliminate Cancerous Tumors
October 30, 2024
Ashdod Port Investing In Startups As Part Of Innovation Strategy
October 29, 2024
BGU Develops Fast Fact Checking Via News Sources Not People
October 28, 2024
Facebook comments